888-500-0370 mbcn@mbcn.org

MBCN News

The U.S. Food and Drug Administration has approved Ibrance (palbociclib)

769006

 

The approval is based on findings from the phase 3 PALOMA-3 trial, in which adding Ibrance to standard Faslodex more than doubled progression-free survival (PFS) in pretreated patients with HR-positive, HER2-negative breast cancer. – See More